---
title: "This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296231890.md"
description: "Wall Street analysts initiated coverage on several stocks Tuesday. B of A Securities gave Definium Therapeutics (DFTX) a Buy rating with a $75 target. Kanzhun (BZ) received a Neutral rating and $74 target from B of A's Miranda Zhuang. Canaccord Genuity assigned Sinda (SIND) a Speculative Buy with a $19 target. Chardan Capital rated Rani Therapeutics (RANI) as Buy with a $6 target, while Canaccord Genuity gave Sunshine Silver Mining (SSMR) a Speculative Buy with a $20 target."
datetime: "2026-08-18T12:45:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296231890.md)
  - [en](https://longbridge.com/en/news/296231890.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296231890.md)
---

# This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   B of A Securities analyst Tazeen Ahmad initiated coverage on **Definium Therapeutics Inc** (NASDAQ:DFTX) with a Buy rating and announced a price target of $75. Definium Therapeutics closed at $45.26 on Monday. See how other analysts view this stock.
-   B of A Securities analyst Miranda Zhuang initiated coverage on **Kanzhun Ltd** (NASDAQ:BZ) with a Neutral rating and announced a price target of $74. Kanzhun shares closed at $15.55 on Monday. See how other analysts view this stock.
-   Canaccord Genuity analyst Peter Bell initiated coverage on **Sinda Ltd** (NYSE:SIND) with a Speculative Buy rating and announced a price target of $19. Sinda closed at $16.69 on Monday. See how other analysts view this stock.
-   Chardan Capital analyst Andreas Argyrides initiated coverage on **Rani Therapeutics Holdings Inc** (NASDAQ:RANI) with a Buy rating and announced a price target of $6. Rani Therapeutics shares closed at $0.80 on Monday. See how other analysts view this stock.
-   Canaccord Genuity analyst Dalton Baretto initiated coverage on **Sunshine Silver Mining & Refining Co** (NYSE:SSMR) with a Speculative Buy rating and announced a price target of $20. Sunshine Silver Mining closed at $16.00 on Monday. See how other analysts view this stock.

Considering buying DFTX stock? Here’s what analysts think:

_Photo via Shutterstock_

### Related Stocks

- [BZ.US](https://longbridge.com/en/quote/BZ.US.md)
- [SSMR.US](https://longbridge.com/en/quote/SSMR.US.md)
- [RANI.US](https://longbridge.com/en/quote/RANI.US.md)
- [SIND.US](https://longbridge.com/en/quote/SIND.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [02076.HK](https://longbridge.com/en/quote/02076.HK.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo](https://longbridge.com/en/news/295787298.md)
- [What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120?](https://longbridge.com/en/news/295821556.md)
- [Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'](https://longbridge.com/en/news/295680444.md)
- [KANZHUN LIMITED Sponsored ADR $BZ Stock Holdings Decreased by The Manufacturers Life Insurance Company](https://longbridge.com/en/news/295905520.md)
- [Cantor Fitzgerald Reaffirms Their Buy Rating on Hyperion DeFi (HYPD)](https://longbridge.com/en/news/295800453.md)